DALLAS, Feb. 4, 2025  — Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced presentations at two upcoming medical meetings. Details of the presentations are as follows:

Bascom Palmer Eye Institute’s 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting

Title: Longitudinal Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients with Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Results from a Long-Term Follow-Up Study (REMAIN)
Session Title: Inherited Retinal Degenerations
Session Date: Saturday, February 8, 2025
Session Time: 6:25 p.m. ET
Presenter: Allen Ho, MD, FACS, FASRS, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital, and Chief Medical Advisor of Nanoscope

Dr. Ho will participate in a panel discussion on inherited retinal dystrophies (IRDs), for several of which, Nanoscope is developing restorative treatments. As part of this, Dr. Ho will discuss 126-week data from Nanoscope’s REMAIN long-term follow-up study of advanced retinitis pigmentosa patients dosed in the RESTORE randomized controlled trial.

The Macula Society 48th Annual Meeting

Title: Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Topline Results from the REMAIN Follow-Up Study (REMAIN)
Session Title: Inherited Retinal Dystrophy I
Session Date: Thursday, February 13, 2025
Session Time: 7:05 a.m. ET
Presenter: Victor Gonzalez, MD, Gulf Coast Eye Institute and REMAIN trial investigator

Dr. Gonzalez will present and discuss long-term follow-up efficacy and safety data of Nanoscope’s MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

Investor Contact:
Argot Partners
212-600-1902
[email protected]

SOURCE Nanoscope Therapeutics